PharmaEssentia (6446) Q1 2025 earnings summary

Executive summary

• Achieved strong revenue growth for Q1 2025, with operating revenue up 97% year-over-year to NTD 3,257 million.

• Net income surged to NTD 1,263.6 million, a 282% increase compared to Q1 2024.

• Gross margin improved to 89% from 88% year-over-year.

• Significant arbitration outcome with AOP Orphan Pharmaceuticals, with some claims dismissed and others pending quantification.

Financial highlights

• Operating revenue: NTD 3,257 million, up from NTD 1,653 million year-over-year.

• Net income: NTD 1,263.6 million, up from NTD 330.4 million year-over-year.

• Basic EPS: NTD 3.80, up from NTD 1.00 year-over-year.

• Cash and cash equivalents: NTD 22,034 million as of March 31, 2025.

• Operating cash flow: NTD 1,061 million, compared to negative NTD 303 million in Q1 2024.

Outlook and guidance

• Board approved 2024 earnings distribution: NTD 1.10 per share cash and share dividend.

• Ongoing investment in clinical trials and new product development, with significant capital committed to R&D and facility expansion.